Sternberg, D W <br/><br/>
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.  [electronic resource] 

 -  Cancer  May 2000 
 - 2037-41 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/(sici)1097-0142(20000501)88:9<2037::aid-cncr8>3.0.co;2-k  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Aged<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cause of Death<br/>Cerebellar Diseases--chemically induced<br/>Cytarabine--administration & dosage<br/>Death, Sudden, Cardiac--etiology<br/>Disease-Free Survival<br/>Drug Eruptions--etiology<br/>Exanthema--chemically induced<br/>Female<br/>Humans<br/>Injections, Intravenous<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neutropenia--chemically induced<br/>Remission Induction<br/>Thrombocytopenia--chemically induced<br/>Treatment Outcome